Specific_JJ Association_NP of_IN Glycoprotein_NP B_NP with_IN Lipid_NP Rafts_NP during_IN Herpes_NP Simplex_NP Virus_NP Entry_NP Herpes_NP simplex_JJ virus_NN (_( HSV_NP )_) entry_NN requires_VBZ the_DT interaction_NN of_IN glycoprotein_NN D_NP (_( gD_NN )_) with_IN a_DT cellular_JJ receptor_NN such_JJ as_IN herpesvirus_NN entry_NN mediator_NN (_( HVEM_NP or_CC HveA_NP )_) or_CC nectin-1_JJ (_( HveC_NP )_) ._SENT However_RB ,_, the_DT fusion_NN mechanism_NN is_VBZ still_RB not_RB understood_VBN ._SENT Since_IN cholesterol-enriched_JJ cell_NN membrane_NN lipid_NN rafts_NNS are_VBP involved_VBN in_IN the_DT entry_NN of_IN other_JJ enveloped_VBN viruses_NNS such_JJ as_IN human_JJ immunodeficiency_NN virus_NN and_CC Ebola_NP virus_NN ,_, we_PP tested_VBD whether_IN HSV_NP entry_NN proceeds_NNS similarly_RB ._SENT Vero_NP cells_NNS and_CC cells_NNS expressing_VBG either_DT HVEM_NP or_CC nectin-1_NP were_VBD treated_VBN with_IN cholesterol-sequestering_VBG drugs_NNS such_JJ as_IN methyl-beta-cyclodextrin_NN or_CC nystatin_NN and_CC then_RB exposed_VBN to_TO virus_NN ._SENT In_IN all_DT cases_NNS ,_, virus_NN entry_NN was_VBD inhibited_VBN in_IN a_DT dose-dependent_JJ manner_NN ,_, and_CC the_DT inhibitory_JJ effect_NN was_VBD fully_RB reversible_JJ by_IN replenishment_NN of_IN cholesterol_NN ._SENT To_TO examine_VB the_DT association_NN of_IN HVEM_NP and_CC nectin-1_JJ with_IN lipid_NN rafts_NNS ,_, we_PP analyzed_VBD whether_IN they_PP partitioned_VBD into_IN nonionic_JJ detergent-insoluble_JJ glycolipid-enriched_JJ membranes_NNS (_( DIG_NP )_) ._SENT There_EX was_VBD no_DT constitutive_JJ association_NN of_IN either_DT receptor_NN with_IN DIG_NP ._SENT Binding_VBG of_IN soluble_JJ gD_NNS or_CC virus_NN to_TO cells_NNS did_VBD not_RB result_VB in_IN association_NN of_IN nectin-1_NN with_IN the_DT raft-containing_NN fractions_NNS ._SENT However_RB ,_, during_IN infection_NN ,_, a_DT fraction_NN of_IN gB_NN but_CC not_RB gC_NN ,_, gD_NNS ,_, or_CC gH_NNS associated_VBN with_IN DIG_NP ._SENT Similarly_RB ,_, when_WRB cells_NNS were_VBD incubated_VBN with_IN truncated_JJ soluble_JJ glycoproteins_NNS ,_, soluble_JJ gB_NN but_CC not_RB gC_NN was_VBD found_VBN associated_VBN with_IN DIG_NP ._SENT Together_RB ,_, these_DT data_NNS favor_VBP a_DT model_NN in_IN which_WDT HSV_NP uses_VBZ gB_NN to_TO rapidly_RB mobilize_VB lipid_NN rafts_NNS that_WDT may_MD serve_VB as_IN a_DT platform_NN for_IN entry_NN and_CC cell_NN signaling_VBG ._SENT It_PP also_RB suggests_VBZ that_IN gB_NN may_MD interact_VB with_IN a_DT cellular_JJ molecule_NN associated_VBN with_IN lipid_NN rafts_NNS ._SENT Herpes_NN simplex_NN virus_NN (_( HSV_NP )_) is_VBZ typically_RB responsible_JJ for_IN mucosal_JJ lesions_NNS of_IN the_DT mouth_NN and_CC genital_JJ organs_NNS in_IN humans_NNS ,_, from_IN where_WRB it_PP spreads_VBZ and_CC establishes_VBZ lifelong_JJ latent_JJ infections_NNS in_IN sensory_JJ neurons_NNS ._SENT Periodically_RB ,_, the_DT virus_NN reactivates_VBZ ,_, multiplies_VBZ ,_, and_CC is_VBZ transported_VBN through_IN the_DT axon_NN back_RB to_TO a_DT portal_NN of_IN entry_NN ._SENT Binding_VBG to_TO host_VB cell_NN surfaces_NNS and_CC entry_NN is_VBZ a_DT complex_JJ process_NN involving_VBG the_DT essential_JJ viral_JJ glycoproteins_NNS B_NN (_( gB_NN )_) ,_, gD_NN ,_, gH_NNS ,_, and_CC gL_NN and_CC multiple_JJ cellular_JJ molecules_NNS ,_, each_DT with_IN various_JJ levels_NNS of_IN affinity_NN and_CC avidity_NN (_( reviewed_VBN in_IN references_NNS and_CC )_) ._SENT In_IN current_JJ models_NNS ,_, gC_NN and/or_CC gB_NN binds_NNS cell_NN surface_NN heparan_JJ sulfate_NN proteoglycans_NNS ,_, bringing_VBG the_DT viral_JJ envelope_NN and_CC plasma_NN membrane_NN close_RB enough_RB for_IN fusion_NN to_TO occur_VB ._SENT As_IN part_NN of_IN this_DT process_NN ,_, gD_NNS must_MD bind_VB to_TO a_DT specific_JJ receptor_NN ,_, which_WDT can_MD be_VB either_DT herpesvirus_NN entry_NN mediator_NN A_NP (_( HVEM_NP or_CC HveA_NP )_) ,_, a_DT member_NN of_IN the_DT tumor_NN necrosis_NN factor_NN receptor_NN family_NN ,_, nectin-1_JJ (_( HveC_NP )_) or_CC nectin-2_JJ (_( HveB_NP )_) ,_, two_CD members_NNS of_IN the_DT Immunoglobulin_NP superfamily_NN ,_, or_CC a_DT particular_JJ type_NN of_IN modified_JJ heparan_JJ sulfate_NN proteoglycans_NNS (_( HSPG_NP )_) 3-OST-3_JJ ._SENT These_DT interactions_NNS may_MD then_RB recruit_VB the_DT other_JJ essential_JJ viral_JJ glycoproteins_NNS into_IN a_DT functional_JJ fusion_NN unit_NN ._SENT In_IN addition_NN ,_, entry_NN may_MD involve_VB plasma_NN membrane_NN rearrangement_NN ,_, signaling_VBG events_NNS ,_, and/or_CC recruitment_NN of_IN additional_JJ cellular_JJ molecules_NNS ._SENT Accumulated_VBN evidence_NN indicates_VBZ that_IN plasma_NN membrane_NN microdomains_NNS ,_, or_CC lipid_NN rafts_NNS ,_, that_WDT are_VBP highly_RB enriched_VBN in_IN cholesterol_NN and_CC sphingolipids_NNS play_VBP a_DT crucial_JJ role_NN in_IN the_DT lateral_JJ organization_NN of_IN the_DT plasma_NN membrane_NN ._SENT It_PP has_VBZ been_VBN proposed_VBN that_IN constitutive_JJ or_CC transient_JJ enrichment_NN of_IN a_DT variety_NN of_IN signaling_VBG molecules_NNS in_IN these_DT defined_VBN microdomains_NNS plays_VBZ a_DT major_JJ role_NN in_IN the_DT organization_NN of_IN signal_NN transduction_NN ._SENT These_DT domains_NNS retain_VBP substantial_JJ lateral_JJ mobility_NN and_CC are_VBP viewed_VBN as_IN highly_RB ordered_VBN moving_VBG platforms_NNS that_WDT carry_VBP specific_JJ proteins_NNS ._SENT Several_JJ viruses_NNS have_VBP taken_VBN advantage_NN of_IN lipid_NN rafts_NNS for_IN one_CD or_CC more_JJR aspects_NNS of_IN their_PP$ replication_NN cycle_NN (_( reviewed_VBN in_IN references_NNS ,_, ,_, ,_, and_CC )_) ._SENT Such_JJ mechanisms_NNS include_VBP viral_JJ particle_NN assembly_NN ,_, budding_VBG from_IN the_DT plasma_NN membrane_NN ,_, signaling_VBG ,_, fusion_NN ,_, and_CC virus_NN entry_NN ._SENT It_PP was_VBD proposed_VBN that_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) entry_NN is_VBZ inhibited_VBN by_IN the_DT presence_NN of_IN drugs_NNS that_WDT remove_VB cholesterol_NN ._SENT The_DT inhibitory_JJ effect_NN was_VBD reversed_VBN by_IN addition_NN of_IN exogenous_JJ cholesterol_NN ,_, indicating_VBG that_IN cholesterol-enriched_JJ lipid_NN rafts_NNS play_VBP an_DT important_JJ role_NN in_IN HIV_NP entry_NN ._SENT Since_IN HIV_NP and_CC HSV_NP enter_VBP cells_NNS by_IN direct_JJ fusion_NN ,_, an_DT intriguing_JJ possibility_NN is_VBZ that_IN rafts_NNS also_RB play_VBP a_DT role_NN in_IN HSV_NP entry_NN (_( reviewed_VBN in_IN reference_NN )_) ._SENT Receptors_NNS for_IN HIV_NP ,_, including_VBG CD4_NP and_CC CCR5_NP ,_, and_CC for_IN murine_JJ leukemia_NN virus_NN are_VBP found_VBN in_IN lipid_NN rafts_NNS ._SENT Binding_VBG of_IN gp120_NN to_TO cells_NNS further_RBR recruits_VBZ a_DT larger_JJR number_NN of_IN HIV_NP receptors_NNS into_IN lipid_NN rafts_NNS ._SENT One_CD evident_JJ question_NN is_VBZ whether_IN the_DT receptors_NNS for_IN HSV_NP associate_NN with_IN lipid_NN rafts_NNS ._SENT It_PP has_VBZ recently_RB been_VBN shown_VBN that_IN some_DT members_NNS of_IN the_DT tumor_NN necrosis_NN factor_NN receptor_NN superfamily_NN ,_, including_VBG CD120a_NP ,_, CD40_NP ,_, and_CC the_DT p75_JJ neurotrophin_NN receptor_NN ,_, are_VBP localized_VBN in_IN rafts_NNS ._SENT Cross-linking_NP of_IN CD40_NP with_IN antibodies_NNS results_NNS in_IN stable_JJ association_NN with_IN lipid_NN rafts_NNS ,_, leading_VBG to_TO activation_NN of_IN tyrosine_NN kinases_NNS and_CC mobilization_NN of_IN tumor_NN necrosis_NN factor_NN receptor-associated_JJ factors_NNS (_( TRAFs_NP )_) ._SENT Such_JJ events_NNS are_VBP essential_JJ for_IN downstream_JJ events_NNS ,_, such_JJ as_IN NF-kappaB_NP activation_NN and_CC interleukin_NN expression_NN ._SENT Epstein-Barr_NP virus_NN has_VBZ exploited_VBN this_DT signaling_VBG route_NN by_IN virtue_NN of_IN the_DT localization_NN of_IN the_DT latent_JJ membrane_NN protein-1_NN (_( LMP1_NP )_) in_IN rafts_NNS ._SENT Association_NP of_IN LMP1_NP with_IN rafts_NNS is_VBZ responsible_JJ for_IN signaling_VBG events_NNS that_WDT mimic_VBP those_DT of_IN a_DT constitutively_RB active_JJ CD40_NP receptor_NN ._SENT An_DT essential_JJ role_NN for_IN rafts_NNS has_VBZ been_VBN described_VBN for_IN the_DT initiation_NN of_IN Fas-mediated_JJ cell_NN death_NN signaling_VBG ._SENT As_IN a_DT tumor_NN necrosis_NN factor_NN receptor-like_JJ protein_NN ,_, HVEM_NP contains_VBZ TRAF-binding_JJ motifs_NNS in_IN its_PP$ cytosolic_JJ tail_NN ,_, and_CC several_JJ reports_NNS demonstrated_VBD activation_NN of_IN NF-kappaB_NP during_IN early_JJ events_NNS of_IN HSV_NP infection_NN ._SENT In_IN addition_NN ,_, several_JJ proteins_NNS are_VBP rapidly_RB phosphorylated_JJ during_IN HSV_NP entry_NN ._SENT Hence_RB ,_, it_PP is_VBZ of_IN interest_NN to_TO know_VB whether_IN HVEM_NP is_VBZ constitutively_RB distributed_VBN in_IN raft-like_JJ structures_NNS on_IN cell_NN surfaces_NNS or_CC redistributes_VBZ there_RB as_IN a_DT consequence_NN of_IN virus_NN binding_NN ._SENT If_IN so_RB ,_, is_VBZ such_PDT an_DT association_NN important_JJ for_IN virus_NN entry_NN ?_SENT Similar_JJ questions_NNS may_MD be_VB asked_VBN about_IN a_DT second_JJ HSV_NP receptor_NN ,_, nectin-1_JJ (_( HveC_NP )_) ._SENT Strong_JJ evidence_NN for_IN membrane_NN raft-dependent_JJ scaffolding_NN of_IN signaling_VBG complexes_NNS has_VBZ come_VBN from_IN studies_NNS on_IN the_DT T-_NN and_CC B-cell_NN immunoreceptors_NNS and_CC the_DT Fcepsilon_NP receptor_NN ,_, all_DT members_NNS of_IN the_DT same_JJ protein_NN family_NN as_IN nectin-1_NN ._SENT Here_RB we_PP present_VB data_NNS investigating_VBG the_DT importance_NN of_IN intact_JJ lipid_NN rafts_NNS at_IN the_DT cell_NN membrane_NN for_IN efficient_JJ virus_NN replication_NN ._SENT Second_RB ,_, we_PP analyzed_VBD whether_IN two_CD HSV_NP receptors_NNS ,_, HVEM_NP and_CC nectin-1_JJ ,_, as_RB well_RB as_IN HSV_NP glycoproteins_NNS showed_VBD an_DT association_NN with_IN lipid_NN rafts_NNS during_IN virus_NN entry_NN ._SENT We_PP found_VBD that_IN HVEM_NP and_CC nectin-1_NP were_VBD not_RB associated_VBN with_IN rafts_NNS in_IN uninfected_JJ cells_NNS and_CC that_IN this_DT distribution_NN did_VBD not_RB change_VB during_IN infection_NN ._SENT Similarly_RB ,_, gD_NNS ,_, gC_NN ,_, and_CC gH_NNS were_VBD not_RB found_VBN associated_VBN with_IN these_DT microdomains_NNS during_IN infection_NN ._SENT By_IN contrast_NN ,_, a_DT fraction_NN of_IN gB_NN was_VBD associated_VBN with_IN rafts_NNS after_IN virus_NN attachment_NN and_CC during_IN entry_NN ._SENT This_DT last_JJ observation_NN points_NNS to_TO a_DT unique_JJ function_NN for_IN gB_NN during_IN HSV_NP entry_NN that_WDT involves_VBZ lipid_NN rafts_NNS and_CC suggests_VBZ the_DT existence_NN of_IN a_DT gB_NN receptor(s)_NN that_WDT is_VBZ enriched_VBN in_IN the_DT cholesterol-rich_JJ microdomains_NNS ._SENT Cells_NNS and_CC viruses_NNS ._SENT |_SYM African_JJ green_JJ monkey_NN kidney_NN (_( Vero_NP )_) and_CC human_JJ embryonic_JJ kidney_NN (_( HEK_NP )_) 293T_JJ cells_NNS were_VBD grown_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN (_( DMEM_NP )_) supplemented_VBD with_IN 5_CD %_NN and_CC 10_CD %_NN fetal_JJ calf_NN serum_NN (_( FCS_NN )_) ,_, respectively_RB ._SENT B78-H1_JJ mouse_NN melanoma_NN cells_NNS expressing_VBG gD_NN receptor_NN HVEM_NP (_( A10_NP )_) or_CC nectin-1_JJ (_( C10_NP )_) were_VBD grown_VBN in_IN DMEM_NP supplemented_VBD with_IN 5_CD %_NN FCS_NN and_CC 500_CD mug_NN of_IN G418_NP per_IN ml_NN ._SENT B78-H1_JJ cells_NNS (_( 3E5_JJ )_) expressing_VBG a_DT green_JJ fluorescent_JJ protein_NN (GFP)-tagged_JJ form_NN of_IN HVEM_NP (_( enhanced_JJ green_JJ fluorescent_JJ protein_NN [_SYM EGFP_NP ]_SYM at_IN the_DT C_NP terminus_NN of_IN HVEM_NP )_) were_VBD cultured_VBN similarly_RB ._SENT These_DT cells_NNS were_VBD shown_VBN to_TO be_VB permissive_JJ for_IN infection_NN by_IN HSV_NP (_( C._NP Whitbeck_NP ,_, unpublished_JJ results_NNS )_) ._SENT HSV-1_NP (_( KOS_NP )_) and_CC an_DT HSV-1_JJ strain_NN (_( KOS/tk12_NP )_) that_WDT carries_VBZ the_DT lacZ_NN gene_NN under_IN the_DT control_NN of_IN the_DT ICP4_NP promoter_NN were_VBD both_DT purified_VBN on_IN sucrose_NN gradients_NNS as_RB described_VBD elsewhere_RB ._SENT HSV-1_NP (_( KOS/tk12_NP )_) and_CC vesicular_JJ stomatitis_NN virus_NN were_VBD kindly_RB provided_VBN by_IN P._NP G._NP Spear_NP and_CC R._NP N._NP Harty_NP ,_, respectively_RB ._SENT Antibodies_NNS and_CC reagents_NNS ._SENT |_SYM Rabbit_NP R47_JJ and_CC R137_JJ sera_NN were_VBD raised_VBN against_IN HSV_NP gC-1_JJ and_CC gH-1/gL-1_JJ ,_, respectively_RB ._SENT Monoclonal_NN antibody_NN (_( MAb_NP )_) DL6_NP recognizes_VBZ a_DT linear_JJ epitope_NN on_IN gD_NN ;_: MAb_NP SS-10_NP was_VBD generated_VBN by_IN immunizing_VBG mice_NNS with_IN gB_NN purified_VBN from_IN an_DT extract_NN of_IN HSV-1-infected_NP BHK_NP cells_NNS (_( unpublished_JJ data_NNS )_) ;_: MAb_NP CW10_NP was_VBD raised_VBN against_IN a_DT recombinant_JJ form_NN of_IN HVEM_NP (_( 200t_NP )_) expressed_VBD in_IN a_DT baculovirus_NN expression_NN system_NN (_( C._NP Whitbeck_NP ,_, unpublished_JJ data_NNS )_) ;_: MAbs_NP CK6_NP and_CC CK41_NP were_VBD raised_VBN against_IN a_DT recombinant_JJ form_NN of_IN nectin-1_NN ._SENT CK41_NP was_VBD also_RB labeled_VBN with_IN phycoerythrin_NN at_IN Molecular_NP Probes_NP ._SENT MAb_NN to_TO flotillin-2/ESA_NN was_VBD obtained_VBN from_IN BD_NP Transduction_NP Laboratories_NPS ._SENT Anti-mouse_NN and_CC anti-rabbit_NN immunoglobulin_NN secondary_JJ antibodies_NNS coupled_VBN to_TO horseradish_NN peroxidase_NN (_( HRP_NP )_) were_VBD purchased_VBN from_IN Kirkegaard_NP and_CC Perry_NP Laboratories_NPS ._SENT Cholera_NN toxin_NN B_NP subunit_NN peroxidase_NN conjugate_VB (_( CTB-HRP_NP )_) was_VBD from_IN Sigma_NP and_CC used_VBN at_IN 40_CD ng/ml_NNS ._SENT 7-Amino-actinomycin_NP D_NP (_( BD_NP Pharmingen_NP )_) was_VBD used_VBN for_IN the_DT exclusion_NN of_IN nonviable_JJ cells_NNS in_IN flow_NN cytometric_JJ assays_NNS following_VBG the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Production_NN and_CC purification_NN of_IN HSV-1_JJ glycoproteins_NNS ._SENT |_SYM gC(457t)_NN contains_VBZ the_DT full_JJ ectodomain_NN of_IN gC1_NN truncated_VBN at_IN residue_NN 457_CD ._SENT gD(285t)_NN ,_, a_DT form_NN of_IN the_DT ectodomain_NN of_IN gD_NNS truncated_VBN at_IN residue_NN 285_CD ,_, binds_VBZ the_DT receptor_NN molecules_NNS HVEM_NP and_CC nectin-1_JJ with_IN higher_JJR affinity_NN than_IN gD(306t)_NN ._SENT The_DT ectodomain_NN comprising_VBG the_DT first_JJ 730_CD amino_NN acids_NNS of_IN gB_NN was_VBD expressed_VBN by_IN recombinant_JJ baculovirus-infected_JJ insect_NN cells_NNS ._SENT Based_VBN on_IN the_DT nucleotide_NN sequence_NN of_IN the_DT HSV-1_JJ gB_NN open_JJ reading_NN frame_NN ,_, we_PP synthesized_VBD two_CD PCR_NP primers_NNS in_IN order_NN to_TO amplify_VB and_CC modify_VB the_DT gB_NN ectodomain_NN coding_VBG region_NN for_IN cloning_VBG and_CC expression_NN in_IN a_DT recombinant_JJ baculovirus_NN ._SENT The_DT first_JJ primer_NN ,_, 5'-CGGGATCCGGCGGCTCCGACTTC-3_NP '_POS ,_, hybridized_VBN to_TO the_DT noncoding_JJ strand_NN of_IN the_DT gB_NP ORF_NP immediately_RB beyond_IN the_DT region_NN coding_VBG for_IN the_DT predicted_VBN signal_NN sequence_NN and_CC incorporated_VBD a_DT BamHI_NP restriction_NN enzyme_NN cleavage_NN site_NN (_( bold_JJ letters_NNS )_) ._SENT The_DT second_JJ primer_NN ,_, 5'-GCGTGATCAGGCGGCGTTGGCGTCGGCGTGGATGAC-3_NP '_POS ,_, hybridized_VBN to_TO the_DT coding_VBG strand_NN of_IN the_DT cloned_VBN gB_NN open_JJ reading_NN frame_NN immediately_RB prior_RB to_TO the_DT transmembrane_JJ region_NN coding_VBG sequence_NN (_( residue_NN 730_CD )_) and_CC incorporated_VBN a_DT BclI_NP restriction_NN enzyme_NN cleavage_NN site_NN (_( bold_JJ letters_NNS )_) ._SENT After_IN cloning_VBG into_IN the_DT BamHI_NP site_NN of_IN the_DT pVT-Bac_JJ transfer_NN vector_NN ,_, the_DT gB_NN coding_VBG region_NN was_VBD positioned_VBN downstream_RB of_IN and_CC in_IN frame_NN with_IN the_DT mellitin_NN signal_NN sequence_NN coding_VBG region_NN ._SENT The_DT resulting_VBG plasmid_NN construct_NN was_VBD cotransfected_VBN with_IN baculovirus_NN DNA_NP (_( Baculogold_NP ;_: Pharmingen_NP )_) into_IN Sf9_NP cells_NNS grown_VBN in_IN monolayer_NN culture_NN ._SENT After_IN 4_CD days_NNS ,_, the_DT culture_NN supernatant_JJ (_( containing_VBG recombinant_JJ progeny_NN virus_NN )_) was_VBD plated_VBN onto_IN Sf9_NP cell_NN monolayers_NNS under_IN Grace_NP 's_POS insect_NN cell_NN medium_NN containing_VBG 1_CD %_NN agarose_NN ._SENT Recombinant_JJ virus_NN plaques_NNS were_VBD picked_VBN and_CC amplified_VBN ,_, and_CC infected_JJ cell_NN cultures_NNS were_VBD screened_VBN for_IN the_DT expression_NN of_IN gB_NN by_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN (_( SDS-PAGE_NP )_) and_CC immunoblot_NN analysis_NN with_IN R69_NP antiserum_NN ._SENT The_DT truncated_JJ protein_NN called_VBD gB(730t)_NN was_VBD purified_VBN from_IN cells_NNS with_IN a_DT DL16_NP immunosorbent_JJ column_NN ._SENT This_DT MAb_NP recognizes_VBZ a_DT dimer-specific_JJ epitope_NN on_IN gB_NN ,_, and_CC hence_RB all_RB of_IN the_DT purified_VBN protein_NN is_VBZ dimeric_JJ ._SENT Conditions_NNS for_IN elution_NN and_CC concentration_NN were_VBD essentially_RB the_DT same_JJ as_RB described_VBN for_IN gD1(306t)_NN ._SENT Cholesterol_NN sequestration_NN and_CC virus_NN entry_NN assay_NN ._SENT |_SYM Vero_NP ,_, A10_NP ,_, or_CC C10_NP cells_NNS were_VBD seeded_VBN in_IN 96-well_NN plates_NNS and_CC grown_VBN overnight_RB to_TO reach_VB about_RB 4_CD x_NN 104_CD cells_NNS per_IN well_RB ._SENT Cells_NNS were_VBD then_RB incubated_VBN for_IN 30_CD min_NN at_IN room_NN temperature_NN with_IN serial_JJ dilutions_NNS of_IN methyl-beta-cyclodextrin_NN (_( MbetaCD_NN )_) or_CC nystatin_NN (_( both_CC reagents_NNS from_IN Sigma_NP )_) in_IN cell_NN culture_NN medium_NN containing_VBG 30_CD mM_NP HEPES_NP ._SENT After_IN three_CD washes_VBZ with_IN medium_NN ,_, cells_NNS were_VBD infected_VBN with_IN HSV-1_NP (_( KOS/tk12_NP )_) at_IN a_DT multiplicity_NN of_IN infection_NN of_IN 10_CD and_CC allowed_VBN to_TO attach_VB to_TO the_DT cells_NNS at_IN 4C_JJ for_IN 1_CD h._NNS The_DT temperature_NN was_VBD then_RB shifted_VBN to_TO 37C_JJ to_TO allow_VB infection_NN to_TO proceed_VB synchronously_RB ._SENT Five_CD hours_NNS later_RBR ,_, cells_NNS were_VBD lysed_VBN by_IN adding_VBG an_DT equal_JJ volume_NN of_IN DMEM_NP containing_VBG 1_CD %_NN NP-40_NP ._SENT beta-Galactosidase_NN activity_NN was_VBD determined_VBN by_IN adding_VBG substrate_NN (_( chlorophenol_NN red-beta-d-galactopyranoside_NN ;_: Roche_NP )_) and_CC measuring_VBG the_DT absorbance_NN at_IN 570_CD nm_NN in_IN a_DT microtiter_NN plate_NN reader_NN ._SENT In_IN replenishment_NN experiments_NNS ,_, Vero_NP cells_NNS were_VBD first_RB treated_VBN with_IN 7.5_CD mM_NNS MbetaCD_JJ for_IN 30_CD min_NN ._SENT MbetaCD_NNS was_VBD washed_VBN out_RP as_IN before_RB ,_, and_CC various_JJ amounts_NNS of_IN water-soluble_JJ cholesterol_NN balanced_VBN with_IN MbetaCD_NP (_( Sigma_NP )_) in_IN DMEM_NP without_IN serum_NN were_VBD added_VBN ._SENT After_IN 30_CD min_NN ,_, the_DT cholesterol-containing_NN medium_NN was_VBD washed_VBN out_RP ,_, cells_NNS were_VBD infected_VBN with_IN HSV-1_NP (_( KOS/tk12_NP )_) ,_, and_CC the_DT process_NN of_IN entry_NN was_VBD assayed_VBN as_RB before_RB ._SENT To_TO deplete_VB cholesterol_NN from_IN purified_VBN virions_NNS ,_, 2_CD x_SYM 106_CD PFU_NP was_VBD incubated_VBN for_IN 30_CD min_NN at_IN room_NN temperature_NN with_IN serial_JJ dilutions_NNS of_IN MbetaCD_NN and_CC then_RB diluted_VBN 60-fold_NN with_IN cell_NN culture_NN medium_NN containing_VBG HEPES_NP ._SENT Vero_NP cells_NNS seeded_VBN into_IN 96-well_NN plates_NNS as_IN above_RB were_VBD infected_VBN with_IN the_DT treated_VBN virus_NN at_IN a_DT multiplicity_NN of_IN infection_NN of_IN 10_CD ,_, and_CC entry_NN was_VBD assayed_VBN as_RB before_RB ._SENT Plaque_NN formation_NN assay_NN ._SENT |_SYM Vero_NP cell_NN monolayers_NNS in_IN 48-well_JJ plates_NNS were_VBD incubated_VBN for_IN 30_CD min_NN at_IN room_NN temperature_NN with_IN serial_JJ dilutions_NNS of_IN MbetaCD_NN in_IN cell_NN culture_NN medium_NN containing_VBG 30_CD mM_NP HEPES_NP ._SENT After_IN three_CD washes_VBZ with_IN medium_NN ,_, cells_NNS were_VBD infected_VBN with_IN 100_CD PFU_NP of_IN HSV-1_NP (_( KOS_NP )_) or_CC vesicular_JJ stomatitis_NN virus_NN at_IN 37C_JJ ._SENT One_CD hour_NN postinfection_NN ,_, the_DT medium_NN was_VBD removed_VBN ,_, and_CC the_DT cells_NNS were_VBD overlaid_VBN with_IN DMEM_NP containing_VBG 1_CD %_NN carboxymethylcellulose_NN and_CC 5_CD %_NN FCS_NN and_CC incubated_VBN for_IN an_DT additional_JJ 24_CD h._NN The_DT cells_NNS were_VBD then_RB fixed_VBN with_IN methanol-acetone_NN (_( 2:1_CD ratio_NN )_) for_IN 20_CD min_NN at_IN -20C_NN and_CC air_NN dried_VBD ._SENT Virus_NN titers_NNS were_VBD determined_VBN by_IN an_DT immunoperoxidase_NN assay_NN with_IN a_DT mixture_NN of_IN anti-gB_NP ,_, -gC_NN ,_, -gD_NNS ,_, and_CC -gH/gL_JJ polyclonal_JJ antisera_NN (_( HSV_NP )_) or_CC stained_VBN with_IN crystal_NN violet_NN (_( vesicular_JJ stomatitis_NN virus_NN )_) ._SENT Flow_NN cytometry_NN ._SENT |_SYM C10_NP or_CC A10_NP seeded_VBD in_IN six-well_NN plates_NNS was_VBD incubated_VBN for_IN 30_CD min_NN at_IN room_NN temperature_NN with_IN serial_JJ dilutions_NNS of_IN MbetaCD_NN in_IN cell_NN culture_NN medium_NN containing_VBG 30_CD mM_NP HEPES_NP ._SENT After_IN three_CD washes_VBZ with_IN medium_NN ,_, cells_NNS were_VBD detached_VBN with_IN 0.02_CD %_NN EDTA_NP in_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) (_( Versene_NP ;_: Gibco-BRL_NP )_) ,_, pelleted_VBD ,_, and_CC resuspended_VBD in_IN 100_CD mul_NN of_IN PBS_NP containing_VBG 3_CD %_NN FCS_NN ._SENT Cells_NNS were_VBD stained_VBN on_IN ice_NN for_IN 1_CD h_NN by_IN the_DT addition_NN of_IN 5_CD mug_NN of_IN CK41_NP per_IN ml_NN directly_RB labeled_VBN with_IN phycoerythrin_NN to_TO detect_VB nectin-1_JJ ._SENT After_IN a_DT PBS_NP wash_NN ,_, cells_NNS were_VBD fixed_VBN with_IN 3_CD %_NN paraformaldehyde_NN in_IN PBS_NP and_CC analyzed_VBD by_IN fluorescence-activated_JJ cell_NN sorting_VBG (_( FACS_NP )_) ._SENT Transient_JJ transfection_NN of_IN 293T_JJ cells_NNS ._SENT |_SYM HEK-293T_NP cells_NNS (_( 80_CD %_NN confluent_NN )_) grown_VBN in_IN a_DT T75_NP flask_NN were_VBD transfected_VBN with_IN 5_CD mug_NN of_IN endotoxin-free_JJ (_( Qiagen_NP )_) purified_VBD plasmid_NN pBEC14_NN ,_, encoding_VBG HVEM_NP ,_, or_CC pBG38_NN ,_, encoding_VBG nectin-1_JJ ,_, with_IN GenePorter_NP ,_, as_RB recommended_VBN by_IN the_DT manufacturer_NN (_( Gene_NP Therapy_NP Systems_NPS )_) ._SENT Twenty-four_NP hours_NNS later_RBR ,_, cells_NNS were_VBD fractionated_VBN on_IN sucrose_NN gradients_NNS as_RB described_VBD below_RB ._SENT Plasmids_NNS pBEC14_NN and_CC pBG38_NN were_VBD kindly_RB provided_VBN by_IN P._NP G._NP Spear_NP ._SENT Isolation_NN of_IN low-density_NN detergent-insoluble_JJ membrane_NN fractions_NNS on_IN sucrose_NN gradients_NNS ._SENT |_SYM Low-density_NP detergent-insoluble_JJ membrane_NN microdomains_NNS were_VBD isolated_VBN essentially_RB as_RB described_VBN by_IN others_NNS with_IN some_DT modifications_NNS ._SENT Briefly_RB ,_, confluent_JJ cell_NN monolayers_NNS in_IN a_DT T75_NP flask_NN were_VBD washed_VBN twice_RB with_IN PBS_NP and_CC then_RB scraped_VBN into_IN 1_CD ml_NN of_IN ice-cold_JJ MNE_NP buffer_NN (_( 25_CD mM_NP MES_NP [_SYM 2-{N-morpholino}ethanesulfonic_JJ acid_NN ,_, pH_NN 6.5_CD ]_SYM ,_, 150_CD mM_NP NaCl_NP ,_, 2_CD mM_NP EDTA_NP )_) containing_VBG 1_CD %_NN Triton_NP X-100_NP (_( Fluka_NP )_) and_CC a_DT cocktail_NN of_IN protease_NN inhibitors_NNS (_( Roche_NP )_) ._SENT Cells_NNS were_VBD further_RBR homogenized_VBN with_IN 10_CD strokes_NNS in_IN a_DT Dounce_NP homogenizer_NN ,_, and_CC then_RB 800_CD mul_NN of_IN the_DT homogenate_NN was_VBD adjusted_VBN to_TO 45_CD %_NN sucrose_NN (_( prepared_VBN in_IN MNE_NP )_) and_CC placed_VBN at_IN the_DT bottom_NN of_IN an_DT ultracentrifuge_NN tube_NN ._SENT A_DT discontinuous_JJ gradient_NN was_VBD formed_VBN by_IN overlaying_VBG the_DT homogenate_NN sequentially_RB with_IN 1.6_CD ml_NN of_IN 35_CD %_NN and_CC of_IN 5_CD %_NN sucrose_NN (_( both_CC prepared_VBN in_IN MNE_NP )_) ._SENT These_DT mixtures_NNS were_VBD centrifuged_VBN at_IN 200,000_CD x_NN g_NN and_CC 4C_JJ for_IN 16_CD h_NN in_IN an_DT SW50_NP swinging-bucket_NN rotor_NN ._SENT The_DT gradient_NN was_VBD fractionated_VBN from_IN the_DT top_NN ,_, and_CC 12_CD fractions_NNS of_IN 400_CD mul_NN each_DT were_VBD collected_VBN ._SENT A_DT 13th_JJ fraction_NN was_VBD obtained_VBN by_IN extracting_VBG the_DT pellet_NN at_IN room_NN temperature_NN with_IN 400_CD mul_NN of_IN 4_CD %_NN SDS_NP in_IN 125_CD mM_NP Tris_NP ,_, pH_NN 6.8_CD ._SENT Isolation_NN of_IN detergent-resistant_JJ membranes_NNS by_IN sequential_JJ centrifugation_NN ._SENT |_SYM Nonionic_JJ detergent-insoluble_JJ glycolipid-enriched_JJ membranes_NNS (_( DIG_NP )_) ,_, which_WDT are_VBP soluble_JJ in_IN octylglucoside_NN ,_, were_VBD prepared_VBN as_IN described_VBN by_IN others_NNS with_IN minor_JJ modifications_NNS ._SENT Briefly_RB ,_, confluent_JJ cells_NNS (_( T25_NP flask_NN )_) were_VBD scraped_VBN into_IN 1_CD ml_NN of_IN ice-cold_JJ MNE_NP buffer_NN containing_VBG 1_CD %_NN Brij-96_NP (_( Fluka_NP )_) and_CC a_DT cocktail_NN of_IN protease_NN inhibitors_NNS (_( Roche_NP )_) ._SENT After_IN 10_CD strokes_NNS in_IN a_DT Dounce_NP homogenizer_NN ,_, the_DT nuclei_NNS were_VBD pelleted_VBN by_IN centrifugation_NN at_IN 500_CD x_NN g_NN for_IN 5_CD min_NN ._SENT Supernatants_NNS were_VBD sequentially_RB centrifuged_VBN at_IN 10,000_CD x_NN g_NN for_IN 10_CD min_NN and_CC then_RB at_IN 200,000_CD x_NN g_NN for_IN 1_CD h_NN with_IN an_DT SW50_NP rotor_NN ._SENT Supernatants_NNS containing_VBG detergent-soluble_JJ membranes_NNS as_RB well_RB as_IN cytosolic_JJ proteins_NNS are_VBP referred_VBN to_TO as_IN DSM_NP ._SENT The_DT insoluble_JJ pellet_NN was_VBD extracted_VBN with_IN 200_CD mul_NN of_IN octylglucoside_NN solution_NN (_( 50_CD mM_NP beta-octylglucopyranoside_NN in_IN 20_CD mM_NP Tris_NP [_SYM pH_NN 8_CD ]_SYM ,_, 200_CD mM_NP NaCl_NP ,_, and_CC protease_NN inhibitors_NNS )_) ._SENT Insoluble_JJ membranes_NNS still_RB attached_VBN to_TO the_DT nuclei_NNS and_CC the_DT pellet_NN from_IN the_DT 10,000_CD x_NN g_NN centrifugation_NN run_NN were_VBD also_RB both_DT reextracted_NN with_IN 200_CD mul_NN of_IN octylglucoside_NN solution_NN ._SENT The_DT octylglucoside-soluble_JJ fractions_NNS were_VBD pooled_VBN and_CC referred_VBN to_TO as_IN DIG_NP ._SENT Measuring_VBG binding_NN of_IN virus_NN or_CC soluble_JJ glycoprotein_NN to_TO the_DT cell_NN surface_NN ._SENT |_SYM Confluent_NP C10_NP cells_NNS (_( T75_NP flask_NN )_) were_VBD washed_VBN once_RB with_IN cold_JJ culture_NN medium_NN containing_VBG 30_CD mM_NP HEPES_NP and_CC then_RB incubated_VBN for_IN 1_CD h_NN at_IN 4C_JJ with_IN HSV-1_NP (_( KOS_NP )_) (_( multiplicity_NN of_IN infection_NN ,_, 10_CD to_TO 20_CD )_) ._SENT Cells_NNS were_VBD then_RB either_RB left_VBN on_IN ice_NN or_CC shifted_VBN to_TO 37C_JJ for_IN various_JJ times_NNS before_IN being_VBG washed_VBN with_IN cold_JJ PBS_NP ._SENT Cells_NNS were_VBD then_RB scraped_VBN into_IN 1_CD ml_NN of_IN ice-cold_JJ MNE_NP buffer_NN containing_VBG 1_CD %_NN Triton_NP X-100_NP ,_, homogenized_VBD ,_, and_CC fractionated_VBD as_RB described_VBN earlier_RBR in_IN the_DT section_NN on_IN isolation_NN of_IN low-density_NN detergent-insoluble_JJ membrane_NN fractions_NNS on_IN sucrose_NN gradients_NNS ._SENT Alternatively_RB ,_, cells_NNS were_VBD grown_VBN to_TO confluency_NN (_( T25_NP flask_NN )_) ,_, washed_VBN ,_, and_CC incubated_VBD as_RB before_RB but_CC now_RB in_IN the_DT presence_NN of_IN 0.1_CD muM_NN purified_VBD soluble_JJ gB(730t)_NN ,_, gC(457t)_NN ,_, or_CC gD(285t_NN )_) ._SENT Cells_NNS were_VBD then_RB either_RB left_VBN on_IN ice_NN or_CC shifted_VBN to_TO 37C_JJ for_IN various_JJ times_NNS before_IN being_VBG washed_VBN with_IN cold_JJ PBS_NP ._SENT The_DT DIG_NP were_VBD then_RB isolated_VBN as_IN described_VBN in_IN the_DT section_NN on_IN isolation_NN of_IN detergent-resistant_JJ membranes_NNS by_IN sequential_JJ centrifugation_NN ._SENT Western_NP and_CC dot_VBP blot_NN analyses_NNS ._SENT |_SYM To_TO analyze_VB the_DT distribution_NN of_IN proteins_NNS in_IN the_DT fractions_NNS obtained_VBN from_IN centrifugation_NN experiments_NNS ,_, an_DT equal_JJ volume_NN of_IN each_DT fraction_NN was_VBD mixed_VBN with_IN SDS-PAGE_NP sample_NN buffer_NN (_( Pierce_NP )_) ,_, and_CC the_DT proteins_NNS were_VBD resolved_VBN by_IN SDS-PAGE_NP (_( Novex_NP )_) under_IN denaturing_VBG conditions_NNS ,_, followed_VBN by_IN Western_NP blotting_VBG ._SENT In_IN some_DT experiments_NNS ,_, the_DT low-density_NN fractions_NNS (_( 3_CD to_TO 6_CD )_) from_IN a_DT sucrose_NN gradient_NN were_VBD pooled_VBN ,_, precipitated_VBN with_IN methanol-chloroform_NN ,_, and_CC solubilized_VBD in_IN gel_NN sample_NN buffer_NN ._SENT After_IN transfer_NN ,_, the_DT membranes_NNS were_VBD reacted_VBN with_IN specific_JJ antibodies_NNS ,_, washed_VBN ,_, and_CC then_RB incubated_VBN with_IN secondary_JJ antibodies_NNS coupled_VBN to_TO HRP_NP ._SENT Bound_JJ antibodies_NNS were_VBD revealed_VBN by_IN enhanced_JJ chemiluminescence_NN (_( ECL_NP ;_: Amersham_NP )_) and_CC exposure_NN to_TO film_NN ._SENT For_IN detection_NN of_IN the_DT ganglioside_NP GM1_NP ,_, 50_CD mul_NN per_IN fraction_NN was_VBD blotted_VBN onto_IN a_DT nitrocellulose_NN membrane_NN ,_, blocked_VBN with_IN PBS_NP containing_VBG 5_CD %_NN nonfat_NN dry_JJ milk_NN and_CC 0.2_CD %_NN Tween_NP ,_, and_CC incubated_VBD with_IN CTB-HRP_NP diluted_VBN in_IN the_DT same_JJ buffer_NN ._SENT Bound_JJ proteins_NNS were_VBD revealed_VBN by_IN ECL_NP as_IN before_RB ._SENT Effect_NN of_IN cholesterol_NN depletion_NN or_CC chelation_NN on_IN HSV_NP entry_NN ._SENT |_SYM One_CD way_NN to_TO tell_VB if_IN lipid_NN rafts_NNS are_VBP important_JJ for_IN virus_NN entry_NN is_VBZ to_TO deplete_VB cells_NNS of_IN cholesterol_NN with_IN agents_NNS that_WDT sequester_VBP cholesterol_NN ,_, such_JJ as_IN cyclodextrins_NNS ,_, or_CC agents_NNS that_IN chelate_JJ cholesterol_NN ,_, such_JJ as_IN statins_NNS ,_, and_CC then_RB examine_VB the_DT effect_NN of_IN such_JJ treatment_NN on_IN virus_NN entry_NN ._SENT We_PP treated_VBD Vero_NP and_CC B78-H1_NP cells_NNS with_IN methyl-beta-cyclodextrin_NN (_( MbetaCD_NN )_) or_CC nystatin_NN for_IN 30_CD min_NN ,_, washed_VBN out_IN the_DT drug_NN ,_, and_CC then_RB infected_VBN them_PP with_IN HSV-1_NP carrying_VBG the_DT lacZ_NP (_( KOS/tk12_NP )_) gene_NN under_IN the_DT control_NN of_IN the_DT ICP4_NP promoter_NN ._SENT At_IN 6_CD h_NN postinfection_NN ,_, the_DT levels_NNS of_IN beta-galactosidase_NN activity_NN in_IN cell_NN extracts_VBZ were_VBD determined_VBN and_CC used_VBN as_IN a_DT measure_NN of_IN virus_NN entry_NN ._SENT Virus_NN entry_NN into_IN Vero_NP cells_NNS was_VBD inhibited_VBN in_IN a_DT dose-dependent_JJ fashion_NN ,_, with_IN 50_CD %_NN inhibition_NN occurring_VBG at_IN 7.5_CD mM_NP MbetaCD_NP and_CC 80_CD mug_NN of_IN nystatin_NN per_IN ml_NN ._SENT To_TO determine_VB whether_IN this_DT effect_NN was_VBD dependent_JJ on_IN a_DT particular_JJ receptor_NN ,_, we_PP repeated_VBD the_DT experiment_NN with_IN cell_NN lines_NNS bearing_VBG a_DT single_JJ HSV_NP receptor_NN ._SENT A10_JJ cells_NNS ,_, which_WDT express_VBP HVEM_NP ,_, and_CC C10_NP cells_NNS ,_, which_WDT express_VBP nectin-1_JJ ,_, were_VBD both_DT derived_VBN by_IN transfection_NN of_IN the_DT mouse_NN melanoma_NN cell_NN line_NN B78-H1_NP ._SENT MbetaCD_NP inhibited_VBD HSV_NP entry_NN into_IN A10_NP and_CC C10_NP cells_NNS in_IN a_DT dose-dependent_JJ fashion_NN ._SENT This_DT indicated_VBD that_IN cholesterol_NN was_VBD important_JJ for_IN HSV_NP entry_NN with_IN either_CC the_DT HVEM_NP or_CC nectin-1_JJ receptor_NN ._SENT Based_VBN on_IN trypan_JJ blue_JJ dye_NN exclusion_NN or_CC with_IN actinomycin_NN D_NN in_IN a_DT flow_NN cytometric_JJ assay_NN ,_, cells_NNS remained_VBD viable_JJ at_IN drug_NN concentrations_NNS as_IN high_JJ as_IN 30_CD mM_NP MbetaCD_NP or_CC 200_CD mug_NN of_IN nystatin_NN per_IN ml_NN (_( data_NNS not_RB shown_VBN )_) ._SENT One_CD possible_JJ explanation_NN for_IN the_DT inhibition_NN of_IN HSV_NP entry_NN by_IN cholesterol-sequestering_VBG drugs_NNS is_VBZ that_IN residual_JJ drug_NN present_JJ in_IN or_CC on_IN the_DT cells_NNS was_VBD toxic_JJ for_IN the_DT virus_NN ._SENT To_TO address_VB this_DT question_NN ,_, HSV-1_NP (_( KOS/tk12_NP )_) virions_NNS were_VBD incubated_VBN with_IN increasing_VBG concentrations_NNS of_IN MbetaCD_NN ,_, then_RB diluted_VBN 60-fold_NN ,_, and_CC tested_VBN for_IN infectivity_NN on_IN Vero_NP cells_NNS ._SENT Treatment_NN of_IN virus_NN with_IN 7.5_CD mM_NP MbetaCD_NP inhibited_VBD its_PP$ ability_NN to_TO infect_VB cells_NNS by_IN 90_CD %_NN ._SENT However_RB ,_, virus_NN treated_VBN with_IN 1_CD mM_NP MbetaCD_NP entered_VBD Vero_NP cells_NNS almost_RB as_RB efficiently_RB as_IN control_NN untreated_JJ virus_NN ._SENT Since_IN cells_NNS were_VBD washed_VBN extensively_RB after_IN MbetaCD_JJ treatment_NN and_CC before_IN infection_NN ,_, it_PP is_VBZ unlikely_JJ that_IN residual_JJ drug_NN left_VBN on_IN the_DT cells_NNS was_VBD as_RB high_JJ as_IN 1_CD mM_NNS ._SENT So_RB ,_, although_IN a_DT high_JJ concentration_NN of_IN MbetaCD_NP was_VBD toxic_JJ for_IN HSV_NP ,_, this_DT toxicity_NN was_VBD not_RB sufficient_JJ to_TO explain_VB the_DT inhibition_NN of_IN entry_NN into_IN cells_NNS treated_VBN with_IN MbetaCD_NP ._SENT Another_DT possibility_NN is_VBZ that_IN MbetaCD_NP inhibited_VBD virus_NN attachment_NN to_TO cells_NNS ._SENT We_PP treated_VBD C10_NP cells_NNS with_IN 30_CD mM_NP MbetaCD_NP ,_, washed_VBD them_PP extensively_RB ,_, and_CC added_VBD HSV-1_NP (_( KOS_NP )_) for_IN 1_CD h_NN at_IN 4C_JJ ._SENT Extracts_VBZ of_IN untreated_JJ and_CC MbetaCD-treated_JJ cells_NNS contained_VBD the_DT same_JJ amount_NN of_IN glycoprotein_NN D_NP (_( gD_NN )_) ,_, as_RB measured_VBN by_IN SDS-PAGE_NP and_CC Western_NP blotting_VBG ._SENT In_IN addition_NN ,_, drug_NN treatment_NN did_VBD not_RB alter_VB the_DT amount_NN of_IN nectin-1_NN detected_VBN in_IN the_DT same_JJ extracts_VBZ ._SENT Surface_NN expression_NN of_IN nectin-1_NP and_CC HVEM_NP (_( not_RB shown_VBN )_) was_VBD not_RB significantly_RB affected_VBN by_IN MbetaCD_NN ,_, as_RB demonstrated_VBN by_IN FACS_NP analysis_NN ._SENT Together_RB ,_, these_DT observations_NNS rule_NN out_IN the_DT possibility_NN that_IN MbetaCD_NP inhibits_VBZ HSV_NP entry_NN by_IN either_DT preventing_VBG virus_NN binding_VBG to_TO cells_NNS or_CC changing_VBG the_DT receptor_NN levels_NNS present_JJ in_IN the_DT cells_NNS ._SENT We_PP also_RB evaluated_VBD the_DT effect_NN of_IN cholesterol_NN sequestration_NN on_IN HSV_NP replication_NN in_IN a_DT plaque_NN formation_NN assay_NN ._SENT Vero_NP cells_NNS were_VBD treated_VBN with_IN MbetaCD_NN for_IN 30_CD min_NN ,_, the_DT drug_NN was_VBD washed_VBN out_RP ,_, and_CC then_RB cells_NNS were_VBD infected_VBN with_IN HSV-1_NP (_( KOS_NP )_) ._SENT As_IN a_DT control_NN ,_, MbetaCD-treated_JJ cells_NNS were_VBD also_RB infected_VBN with_IN vesicular_JJ stomatitis_NN virus_NN ,_, which_WDT is_VBZ known_VBN to_TO be_VB raft_NN independent_JJ ._SENT Plaques_NNS were_VBD stained_VBN 24_CD h_NN later_RBR and_CC counted_VBN ._SENT The_DT number_NN of_IN HSV_NP plaques_NNS was_VBD reduced_VBN in_IN a_DT dose-dependent_JJ manner_NN ,_, with_IN 50_CD %_NN inhibition_NN occurring_VBG at_IN 10_CD mM_NP MbetaCD_NP ._SENT In_IN contrast_NN up_RP to_TO 30_CD muM_NN MbetaCD_NN did_VBD not_RB reduce_VB the_DT number_NN of_IN vesicular_JJ stomatitis_NN virus_NN plaques_NNS made_VBD ._SENT These_DT results_NNS underscore_VBP the_DT importance_NN of_IN plasma_NN membrane_NN cholesterol_NN content_NN for_IN efficient_JJ viral_JJ replication_NN and_CC support_VB the_DT observations_NNS made_VBN in_IN the_DT entry_NN assays_NNS ._SENT In_IN addition_NN ,_, we_PP observed_VBD that_IN the_DT few_JJ plaques_NNS that_WDT formed_VBD in_IN cells_NNS treated_VBN with_IN MbetaCD_NP were_VBD markedly_RB smaller_JJR (_( not_RB shown_VBN )_) ._SENT However_RB ,_, plaque_NN sizes_NNS were_VBD normal_JJ after_IN longer_JJR periods_NNS of_IN infection_NN ,_, and_CC the_DT reduction_NN in_IN plaque_NN number_NN in_IN drug-treated_JJ cells_NNS was_VBD less_JJR severe_JJ (_( not_RB shown_VBN )_) ._SENT These_DT observations_NNS suggest_VBP that_IN cholesterol_NN depletion_NN imposes_VBZ a_DT delay_NN in_IN the_DT onset_NN of_IN infection_NN by_IN HSV_NP ._SENT Cholesterol_NN replenishment_NN reverses_VBZ effect_NN of_IN MbetaCD_NP ._SENT |_SYM To_TO show_VB that_IN the_DT inhibitory_JJ drug_NN effects_NNS were_VBD specific_JJ ,_, we_PP replaced_VBD the_DT cholesterol_NN after_IN sequestration_NN and_CC tested_VBN whether_IN HSV_NP entry_NN was_VBD restored_VBN ._SENT We_PP treated_VBD Vero_NP cells_NNS with_IN 7.5_CD mM_NNS MbetaCD_JJ for_IN 30_CD min_NN ,_, a_DT concentration_NN that_WDT inhibited_VBD entry_NN by_IN 50_CD %_NN (_( Fig._NN ,_, arrow_NN )_) ._SENT The_DT drug_NN was_VBD washed_VBN out_RP ,_, and_CC increasing_VBG concentrations_NNS of_IN cholesterol_NN were_VBD then_RB added_VBN to_TO reconstitute_VB plasma_NN membrane_NN cholesterol_NN levels_NNS ._SENT Excess_JJ cholesterol_NN was_VBD washed_VBN out_RP ,_, and_CC the_DT cells_NNS were_VBD infected_VBN with_IN HSV-1_NP (_( KOS/tk12_NP )_) ._SENT The_DT addition_NN of_IN cholesterol_NN completely_RB reversed_VBD the_DT inhibitory_JJ effect_NN of_IN MbetaCD_NN in_IN a_DT dose-dependent_JJ fashion_NN ._SENT We_PP conclude_VBP that_IN plasma_NN membrane_NN cholesterol_NN is_VBZ very_RB important_JJ during_IN HSV_NP entry_NN because_IN sequestration_NN or_CC chelation_NN of_IN cholesterol_NN prior_RB to_TO HSV_NP infection_NN inhibited_VBD entry_NN ,_, an_DT effect_NN reversed_VBN by_IN the_DT addition_NN of_IN exogenous_JJ cholesterol_NN ._SENT Since_IN rafts_NNS are_VBP maintained_VBN via_IN cholesterol_NN (_( reviewed_VBN in_IN reference_NN )_) ,_, we_PP wondered_VBD whether_IN inhibition_NN of_IN HSV_NP entry_NN mediated_VBN by_IN cholesterol-sequestering_NN drugs_NNS was_VBD due_JJ to_TO raft_VB dispersion_NN ._SENT Effect_NN of_IN cholesterol_NN depletion_NN after_IN HSV_NP entry_NN ._SENT |_SYM To_TO test_VB whether_IN cholesterol_NN sequestration_NN had_VBD an_DT effect_NN after_IN entry_NN but_CC during_IN replication_NN ,_, Vero_NP cells_NNS were_VBD first_RB infected_VBN with_IN HSV-1_NP (_( KOS/tk12_NP )_) and_CC at_IN various_JJ times_NNS postinfection_NN treated_VBN for_IN 30_CD min_NN with_IN 7.5_CD mM_NP MbetaCD_NP ._SENT MbetaCD_NP markedly_RB inhibited_VBD HSV_NP replication_NN when_WRB it_PP was_VBD added_VBN at_IN 30_CD min_NN postinfection_NN ,_, but_CC the_DT level_NN of_IN inhibition_NN decreased_VBD when_WRB the_DT drug_NN was_VBD added_VBN at_IN later_JJR times_NNS ._SENT Normal_JJ entry_NN was_VBD observed_VBN when_WRB MbetaCD_NP was_VBD applied_VBN to_TO cells_NNS between_IN 2_CD to_TO 3_CD h_NN after_IN infection_NN ._SENT Interestingly_RB ,_, at_IN any_DT time_NN following_VBG infection_NN ,_, MbetaCD-mediated_JJ inhibition_NN of_IN entry_NN was_VBD not_RB reversible_JJ by_IN replenishment_NN of_IN cholesterol_NN ._SENT These_DT data_NNS suggest_VBP that_IN rafts_NNS may_MD be_VB important_JJ during_IN the_DT early_JJ events_NNS of_IN HSV_NP replication_NN ,_, like_IN fusion_NN ,_, but_CC play_VB no_DT role_NN later_RBR ,_, once_IN virus_NN entry_NN has_VBZ occurred_VBN ._SENT They_PP also_RB provide_VBP further_JJR evidence_NN that_IN MbetaCD_NP is_VBZ not_RB toxic_JJ for_IN cells_NNS ._SENT Distribution_NN of_IN HSV_NP receptors_NNS on_IN the_DT plasma_NN membrane_NN :_: are_VBP the_DT viral_JJ receptors_NNS HVEM_NP and_CC nectin-1_NP found_VBD in_IN rafts_NNS ?_SENT |_SYM All_PDT these_DT experiments_NNS suggested_VBD that_IN cholesterol-rich_JJ rafts_NNS might_MD play_VB a_DT role_NN in_IN HSV_NP entry_NN ._SENT One_CD possibility_NN is_VBZ that_IN HSV_NP receptors_NNS are_VBP associated_VBN with_IN rafts_NNS or_CC redistribute_VB into_IN rafts_NNS as_IN a_DT consequence_NN of_IN binding_VBG to_TO virus_NN glycoproteins_NNS ._SENT To_TO assess_VB these_DT possibilities_NNS ,_, we_PP used_VBD sucrose_NN gradients_NNS to_TO isolate_VB low-density_NN detergent-insoluble_JJ fractions_NNS from_IN cells_NNS ._SENT B78_NN cells_NNS stably_RB expressing_VBG HVEM-GFP_NP or_CC nectin-1_NP were_VBD extracted_VBN in_IN Triton_NP X-100_NP and_CC analyzed_VBD for_IN receptor_NN distribution_NN into_IN low-_NN and_CC high-density_NN fractions_NNS ._SENT HVEM-GFP_NP was_VBD used_VBN because_IN its_PP$ larger_JJR molecular_JJ size_NN allowed_VBD us_PP to_TO visualize_VB it_PP more_RBR easily_RB than_IN native_JJ HVEM_NP by_IN Western_NP blotting_VBG ._SENT The_DT ganglioside_NN GM1_NP and_CC the_DT protein_NN flotillin-2_NN are_VBP both_CC associated_VBN with_IN rafts_NNS and_CC were_VBD used_VBN as_IN markers_NNS ._SENT GM1_NP was_VBD mostly_RB enriched_VBN in_IN the_DT low-density_NN fractions_VBZ (_( numbers_NNS 3_CD to_TO 7_CD )_) ,_, and_CC a_DT substantial_JJ portion_NN of_IN flotillin-2_NN was_VBD recovered_VBN in_IN fractions_NNS 4_CD and_CC 5_CD ._SENT This_DT is_VBZ in_IN agreement_NN with_IN other_JJ reports_NNS ._SENT Neither_CC HVEM-GFP_NP nor_CC nectin-1_NP was_VBD found_VBN in_IN the_DT low-density_NN sucrose_NN fractions_NNS (_( numbers_NNS 1_CD to_TO 6_CD )_) ._SENT These_DT proteins_NNS were_VBD only_RB recovered_VBN in_IN the_DT high-density_NN fractions_VBZ (_( numbers_NNS 7_CD to_TO 12_CD )_) ,_, where_WRB nonraft_NN proteins_NNS are_VBP found_VBN ._SENT Similarly_RB ,_, when_WRB 293T_JJ cells_NNS were_VBD transiently_RB transfected_VBN with_IN plasmids_NNS expressing_VBG wild-type_NP HVEM_NP or_CC nectin-1_NP ,_, neither_DT receptor_NN was_VBD found_VBN in_IN the_DT GM1/flotillin-2-rich_NP fractions_NNS ._SENT As_IN a_DT second_JJ approach_NN ,_, we_PP used_VBD a_DT more_RBR general_JJ procedure_NN for_IN two_CD reasons_NNS ._SENT First_RB ,_, some_DT proteins_NNS ,_, such_JJ as_IN prion_NN protein_NN ,_, are_VBP enriched_VBN in_IN semiordered_JJ lipid_NN margins_NNS ,_, located_VBN at_IN the_DT interface_NN between_IN the_DT highly_RB ordered_VBN lipid_NN raft_NN domains_NNS and_CC the_DT fluid_JJ glycerolipid_JJ membrane_NN domain_NN ._SENT These_DT margin_NN domains_NNS are_VBP solubilized_VBN in_IN Triton_NP X-100_NP but_CC not_RB in_IN the_DT milder_JJR detergent_NN Brij-96_NN ._SENT Second_JJ ,_, due_JJ to_TO strong_JJ interactions_NNS with_IN the_DT cytoskeleton_NN ,_, some_DT raft-associated_JJ molecules_NNS ,_, such_JJ as_IN TRAF-3_NP ,_, only_RB minimally_RB associate_NN with_IN low-density_NN fractions_NNS in_IN sucrose_NN gradients_NNS but_CC are_VBP mainly_RB recovered_VBN in_IN the_DT pellet_NN of_IN the_DT gradient_NN together_RB with_IN the_DT cytoskeleton_NN ._SENT Nectin-1_JJ associates_NNS with_IN afadin_NN ,_, which_WDT in_IN turn_NN associates_NNS with_IN the_DT cytoskeleton_NN via_IN actin_NN ._SENT Thus_RB ,_, it_PP was_VBD possible_JJ that_IN one_PP or_CC both_DT receptors_NNS might_MD be_VB minimally_RB associated_VBN with_IN rafts_NNS ._SENT A_DT less_RBR stringent_JJ way_NN to_TO examine_VB such_JJ interactions_NNS is_VBZ to_TO solubilize_VB the_DT membranes_NNS with_IN a_DT milder_JJR detergent_NN ,_, such_JJ as_IN Brij-96_NP ,_, and_CC then_RB to_TO use_VB centrifugation_NN to_TO separate_VB glycolipid_JJ domains_NNS (_( DIG_NP )_) and_CC the_DT cytoskeleton_NN ._SENT Then_RB DIG_NP which_WDT also_RB contain_VBP rafts_NNS are_VBP solubilized_VBN and_CC separated_VBN from_IN the_DT cytoskeleton_NN with_IN octylglycoside_NN ._SENT Therefore_RB ,_, we_PP lysed_VBD HVEM-GFP_NP cells_NNS and_CC C10_JJ cells_NNS with_IN Triton_NP X-100_NP or_CC Brij-96_NP and_CC isolated_VBD the_DT DIG_NP fractions_NNS ._SENT In_IN no_DT case_NN was_VBD HVEM_NP found_VBN in_IN fractions_NNS containing_VBG DIG_NP ,_, although_IN a_DT substantial_JJ amount_NN of_IN flotillin-2_NN and_CC all_DT of_IN GM1_NP were_VBD detected_VBN in_IN these_DT fractions_NNS ._SENT These_DT results_NNS are_VBP consistent_JJ with_IN those_DT obtained_VBN by_IN sucrose_NN gradient_JJ centrifugation_NN ._SENT Similarly_RB ,_, nectin-1_NN was_VBD not_RB detected_VBN in_IN the_DT DIG_NP recovered_VBD from_IN cells_NNS lysed_VBN with_IN Triton_NP X-100_NP (_( Fig._NN ,_, top_JJ panel_NN )_) ._SENT However_RB ,_, a_DT small_JJ but_CC reproducible_JJ fraction_NN of_IN nectin-1_NN was_VBD found_VBN associated_VBN with_IN DIG_NP recovered_VBD from_IN cells_NNS solubilized_VBN with_IN Brij-96_NP ,_, suggesting_VBG that_IN a_DT small_JJ amount_NN of_IN the_DT protein_NN may_MD associate_VB with_IN rafts_NNS (_( Fig._NN ,_, bottom_JJ )_) ._SENT However_RB ,_, the_DT amount_NN of_IN nectin-1_NN found_VBN in_IN the_DT DIG_NP fraction_NN never_RB exceeded_VBD the_DT amount_NN of_IN the_DT transferrin_NN receptor_NN found_VBN in_IN this_DT fraction_NN (_( not_RB shown_VBN )_) ._SENT The_DT transferrin_NN receptor_NN is_VBZ a_DT classical_JJ marker_NN of_IN a_DT nonraft_NN membrane_NN protein_NN ._SENT This_DT suggests_VBZ that_IN nectin-1_NN detected_VBN in_IN DIG_NP did_VBD not_RB come_VB from_IN a_DT pool_NN of_IN molecules_NNS associated_VBN with_IN rafts_NNS but_CC rather_RB was_VBD a_DT contaminant_NN of_IN the_DT fractionation_NN procedure_NN ._SENT We_PP therefore_RB conclude_VBP that_IN HVEM_NP and_CC nectin-1_JJ are_VBP not_RB associated_VBN with_IN lipid_NN raft_NN fractions_NNS in_IN HVEM_NP cells_NNS or_CC nectin-1_JJ cells_NNS regardless_RB of_IN the_DT fractionation_NN technique_NN or_CC the_DT detergent_NN used_VBD ._SENT Distribution_NN of_IN HSV_NP glycoproteins_NNS on_IN plasma_NN membrane_NN during_IN entry_NN ._SENT |_SYM We_PP asked_VBD whether_IN HSV_NP receptors_NNS redistribute_VBP into_IN lipid_NN rafts_NNS after_IN initial_JJ virus_NN association_NN or_CC during_IN entry_NN ._SENT Manes_NP et_FW al._FW proposed_VBN this_DT process_NN for_IN HIV_NP gp120_NP and_CC its_PP$ receptors_NNS ._SENT Accordingly_RB ,_, C10_NP cells_NNS were_VBD infected_VBN with_IN HSV_NP and_CC lysed_VBN with_IN Triton_NP X-100_NP at_IN 0_CD ,_, 15_CD ,_, or_CC 30_CD min_NN postinfection_NN ._SENT Lysates_NNS were_VBD subjected_VBN to_TO sucrose_NN gradient_NN centrifugation_NN ._SENT GM1_NP was_VBD detected_VBN with_IN the_DT low-density_NN fractions_VBZ 3_CD to_TO 6_CD at_IN all_DT three_CD times_NNS postinfection_NN ._SENT To_TO facilitate_VB analysis_NN ,_, we_PP chose_VBD a_DT representative_JJ nonraft_NN fraction_NN (_( fraction_NN 11_CD )_) and_CC compared_VBN this_DT with_IN pooled_JJ fractions_NNS 3_CD to_TO 6_CD (_( Fig._NN and_CC )_) ._SENT The_DT raft_NN marker_NN flotillin-2_NN was_VBD found_VBN primarily_RB in_IN pooled_JJ fractions_NNS 3_CD to_TO 6_CD ._SENT However_RB ,_, nectin-1_JJ was_VBD excluded_VBN from_IN these_DT fractions_NNS and_CC instead_RB was_VBD located_VBN entirely_RB in_IN the_DT nonraft_NN fractions_NNS at_IN 0_CD ,_, 15_CD ,_, and_CC 30_CD min_NN postinfection_NN ._SENT During_IN this_DT time_NN period_NN ,_, gD_NNS also_RB was_VBD restricted_VBN to_TO nonraft_NN fractions_NNS ,_, suggesting_VBG that_IN any_DT association_NN of_IN gD_NNS with_IN nectin-1_NN at_IN the_DT time_NN of_IN or_CC shortly_RB after_IN infection_NN occurred_VBN outside_IN lipid_NN rafts_NNS ._SENT Similarly_RB ,_, gC_NN and_CC gH_NN ,_, two_CD other_JJ glycoproteins_NNS involved_VBN in_IN entry_NN ,_, were_VBD restricted_VBN to_TO nonraft_NN fractions_NNS ._SENT Interestingly_RB ,_, a_DT substantial_JJ fraction_NN of_IN gB_NN associated_VBN with_IN rafts_NNS at_IN 4C_JJ ,_, and_CC this_DT proportion_NN remained_VBD constant_JJ through_IN the_DT early_JJ steps_NNS of_IN entry_NN ._SENT However_RB ,_, when_WRB purified_VBN virions_NNS were_VBD fractionated_VBN on_IN a_DT sucrose_NN gradient_NN in_IN the_DT absence_NN of_IN cells_NNS ,_, gB_NN could_MD not_RB be_VB detected_VBN in_IN raft_NN fractions_NNS (_( not_RB shown_VBN )_) ._SENT Similarly_RB ,_, gB_NN was_VBD not_RB selectively_RB associated_VBN with_IN DIG_NP compared_VBN to_TO gD_NN and_CC gH/gL_NN when_WRB transfected_VBN in_IN 293T_JJ cells_NNS (_( not_RB shown_VBN )_) ._SENT Thus_RB ,_, it_PP is_VBZ unlikely_JJ that_IN gB_NN interacts_VBZ with_IN rafts_NNS during_IN the_DT extraction_NN procedure_NN or_CC during_IN sedimentation_NN ._SENT The_DT association_NN of_IN gB_NN with_IN rafts_NNS requires_VBZ the_DT initial_JJ binding_NN of_IN the_DT virus_NN to_TO a_DT cell_NN surface_NN ._SENT Distribution_NN of_IN soluble_JJ HSV_NP glycoproteins_NNS after_IN association_NN with_IN plasma_NN membrane_NN ._SENT |_SYM These_DT studies_NNS suggested_VBD that_IN gB_NN interacts_VBZ specifically_RB with_IN lipid_NN rafts_NNS during_IN virus_NN entry_NN ._SENT Because_IN this_DT association_NN was_VBD observed_VBN at_IN time_NN zero_NN ,_, it_PP was_VBD possible_JJ that_IN the_DT ectodomain_NN of_IN virion_NN gB_NN might_MD associate_VB with_IN a_DT raft-associated_JJ cell_NN molecule_NN ._SENT To_TO test_VB this_DT ,_, we_PP incubated_VBD cells_NNS with_IN purified_VBN ectodomains_NNS of_IN gB_NN ,_, gC_NN ,_, or_CC gD_NNS and_CC evaluated_VBD the_DT association_NN of_IN the_DT different_JJ glycoproteins_NNS with_IN the_DT DIG_NP fraction_NN ._SENT Also_RB ,_, to_TO mimic_VB the_DT situation_NN of_IN virus_NN entry_NN ,_, the_DT proteins_NNS were_VBD added_VBN to_TO the_DT cells_NNS at_IN 4C_JJ and_CC the_DT temperature_NN was_VBD shifted_VBN to_TO 37C_JJ for_IN various_JJ times_NNS ._SENT At_IN 4C_JJ and_CC time_NN zero_NN ,_, soluble_JJ gB_NN was_VBD already_RB associated_VBN with_IN the_DT DIG_NP fraction_NN (_( Fig._NN ,_, 0_CD min_NN )_) ._SENT Interestingly_RB ,_, the_DT apparent_JJ amount_NN and_CC proportion_NN of_IN gB_NN in_IN the_DT DIG_NP fraction_NN increased_VBD during_IN incubation_NN at_IN 37C_JJ for_IN up_IN to_TO 1_CD h_NN (_( Fig._NN ,_, DIG_NP )_) ._SENT During_IN the_DT same_JJ period_NN ,_, the_DT proportion_NN of_IN the_DT full-size_JJ gB_NN ectodomain_NN found_VBN in_IN the_DT DSM_NP was_VBD constant_JJ ,_, although_IN there_EX was_VBD an_DT accumulation_NN of_IN degradation_NN products_NNS over_IN time_NN (_( Fig._NN ,_, DSM_NP )_) ._SENT By_IN contrast_NN ,_, gC_NN and_CC gD_JJ (_( Fig._NN ,_, lower_JJR panel_NN )_) were_VBD almost_RB excluded_VBN from_IN DIG_NP at_IN all_DT time_NN points_NNS ._SENT The_DT low_JJ levels_NNS of_IN gD_NNS found_VBN in_IN DIG_NP are_VBP consistent_JJ with_IN the_DT low_JJ levels_NNS of_IN nectin-1_NN found_VBN in_IN this_DT fraction_NN (_( Fig._NN ,_, top_JJ panel_NN )_) ._SENT The_DT fact_NN that_IN gC_NN was_VBD also_RB found_VBN exclusively_RB in_IN the_DT DSM_NP is_VBZ important_JJ because_IN it_PP ,_, like_IN gB_NN ,_, associates_NNS with_IN heparan_JJ sulfate_NN on_IN cells_NNS ._SENT Thus_RB ,_, it_PP is_VBZ unlikely_JJ that_IN the_DT distribution_NN of_IN gB_NN into_IN DIG_NP is_VBZ related_VBN to_TO heparan_JJ sulfate_NN binding_NN ._SENT If_IN so_RB ,_, gB_NN but_CC not_RB gC_NN would_MD associate_VB with_IN a_DT specific_JJ type_NN of_IN HSPG_NP enriched_VBD in_IN DIG_NP ,_, or_CC gB_NN and_CC gC_NN could_MD have_VB differential_JJ effects_NNS when_WRB bound_VBN to_TO HSPG_NP ._SENT The_DT association_NN of_IN soluble_JJ gB_NN with_IN DIG_NP corroborates_VBZ our_PP$ observations_NNS made_VBN with_IN virion_NN gB_NN ._SENT Together_RB ,_, the_DT data_NNS suggest_VBP that_IN the_DT interaction_NN of_IN gB_NN with_IN rafts_NNS does_VBZ not_RB depend_VB on_IN its_PP$ transmembrane_NN domain_NN or_CC carboxy_JJ terminus_NN but_CC is_VBZ mediated_VBN by_IN the_DT ectodomain_NN ._SENT Requirement_NN of_IN cholesterol_NN for_IN HSV_NP entry_NN ._SENT |_SYM 